1	Synergistic Role of NK Cells and Monocytes in Promoting Atherogenesis in Severe
2	COVID-19 Patients.
3	Manuja Gunasena <sup>1,2#</sup> , Mario Alles <sup>1#</sup> , Yasasvi Wijewantha <sup>1#</sup> , Will Mulhern <sup>1</sup> , Emily Bowman <sup>3</sup> ,
4	Janelle Gabriel <sup>3</sup> , Aaren Kettelhut <sup>3</sup> , Amrendra Kumar <sup>4</sup> , Krishanthi Weragalaarachchi <sup>1</sup>
5	Dhanuja Kasturiratna <sup>5</sup> , Jeffrey C Horowitz <sup>6,9</sup> , Scott Scrape <sup>4</sup> , Sonal R Pannu <sup>6,9</sup> , Shan-Lu Liu <sup>1,2</sup> ,
6	Anna Vilgelm <sup>4</sup> , Saranga Wijeratne <sup>7</sup> , Joseph S Bednash <sup>6,9</sup> , Thorsten Demberg <sup>8</sup> , Nicholas T
7	Funderburg <sup>2</sup> and Namal P.M. Liyanage* <sup>1,2</sup>
8	
9	<sup>1</sup> Department of Microbial Infection and Immunity, College of Medicine, The Ohio State
10	University, <sup>2</sup> Department of Veterinary Bioscience, College of Veterinary Medicine, The Ohio
11	State University, <sup>3</sup> School of Health and Rehabilitation Sciences, College of Medicine, the Ohio
12	State University, <sup>4</sup> Department of pathology, College of Medicine, The Ohio State University
13	<sup>5</sup> Department of Mathematics and Statistics, Northern Kentucky University, KY, Highland
14	Heights, KY, USA, <sup>6</sup> Department of Internal Medicine, College of Medicine, The Ohio State
15	University, <sup>7</sup> The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner
16	Research Institute at Nationwide Children's Hospital, Columbus, Ohio. <sup>8</sup> Department of
17	Pediatrics, Baylor College of Medicine, Houston, TX, <sup>9</sup> Dorothy M. Davis Heart and Lung
18	Research Institute, College of Medicine, The Ohio State University.
19	
20	# equally contributed
21 22 23 24 25 26 27 28	*Corresponding author: Namal P.M. Liyanage Assistant Professor 788 Biomedical Research Tower 460 W 12th Ave, Columbus OH 43210 Phone: 614 293 9114 E-Mail: <u>namal.liyanage@osumc.edu</u>
29	

# 30 Abstract:

31	Clinical data demonstrate an increased predisposition to cardiovascular disease (CVD) following
32	severe COVID-19 infection. This may be driven by a dysregulated immune response associated
33	with severe disease. Monocytes and vascular tissue resident macrophages play a critical role in
34	atherosclerosis, the main pathology leading to ischemic CVD. Natural killer (NK) cells are a
35	heterogenous group of cells that are critical during viral pathogenesis and are known to be
36	dysregulated during severe COVID-19 infection. Their role in atherosclerotic cardiovascular
37	disease has recently been described. However, the contribution of their altered phenotypes to
38	atherogenesis following severe COVID-19 infection is unknown. We demonstrate for the first
39	time that during and after severe COVID-19, circulating proinflammatory monocytes and
40	activated NK cells act synergistically to increase uptake of oxidized low-density lipoprotein (Ox-
41	LDL) into vascular tissue with subsequent foam cell generation leading to atherogenesis despite
42	recovery from acute infection. Our data provide new insights, revealing the roles of
43	monocytes/macrophages, and NK cells in COVID-19-related atherogenesis.
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	

# 56 Introduction:

57	An increasing body of evidence suggests that coronavirus disease 2019 (COVID-19), caused by
58	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) predisposes affected
59	individuals to CVDs including acute myocardial infarction and stroke <sup>1</sup> . Atherosclerosis is the
60	main pathophysiological process underlying most cases of CVDs in humans <sup>2</sup> . It is a chronic
61	inflammatory condition which can lead to coronary artery calcification and an overall
62	prothrombotic state culminating in CVD pathology <sup>3,4</sup> . Monocytes and macrophages are central
63	to the pathogenesis of atherosclerosis. Upon recruitment to the intima of arteries following lipid
64	deposition, circulating monocytes differentiate into a broad spectrum of proinflammatory
65	macrophages (M1 type), lipid-laden foam cells, and dendritic cells <sup>5</sup> .
66	Recent studies using coronary autopsy specimens from patients with COVID-19 revealed that
67	infiltrating macrophages are infected by SARS-CoV-2, with foam cells, a hallmark of
68	atherosclerosis at all stages of the disease, being more susceptible to SARS-CoV-2 infection
69	than other macrophages. Furthermore, SARS-CoV-2 was found to induce a strong pro-
70	atherogenic inflammatory response in both macrophages and foam cells, a phenomenon that
71	was largely recapitulated in an ex vivo SARS-CoV-2 infection of human vascular explants,
72	suggesting a potential mechanism for increased risk of atherosclerosis following COVID-19
73	infection <sup>6</sup> . Monocytes and macrophages are in constant direct and indirect (via soluble
74	mediators) communication with several other immune cells.
75	During viral pathogenesis, one of the earliest cell types to arrive at the site of infection are NK
76	cells which in partnership with monocytes/macrophages, trigger an immune response. A new
77	understanding of the functions of monocytes and macrophages in health and diseases is
78	emerging where NK cells play a crucial intermediary role <sup>7</sup> . The role of NK cells in "normal"
79	atherosclerosis has been described previously. However, the phenotypic and functional
80	associations of NK cells in COVID-19-associated atherosclerosis are not fully known.

81 For the first time, we demonstrate that in the peripheral blood of patients during and after severe 82 COVID-19, monocytes and NK cells are activated and may influence the consumption of 83 oxidized lipids from the circulation. This ongoing process results in the generation of foam cells 84 in vascular tissue, suggestive of persistent atherogenesis even after recovery. In vitro 85 experiments and correlational analyses have led to a mechanistic interpretation that suggests a 86 direct crosstalk between activated NK cells and macrophages during COVID-19, leading to an 87 increased uptake of Ox-LDL from the environment, subsequently resulting in foam cell 88 generation and atherogenesis.

89

#### 90 Material and Methods:

91 Patient characteristics: Patients were enrolled in the Ohio State University Intensive Care Unit 92 Registry (BuckICU, IRB: 2020H0175) at the Ohio State University Wexner Medical Center and 93 the James Cancer Hospital and Solove Research Institute between April 2020 and January 94 2021. BuckICU is a multi-disciplinary biorepository project that collects human biospecimens 95 and associated clinical data from critically ill patients admitted to the ICU (severe) with 96 respiratory failure, defined as any increase in respiratory support (supplemental oxygen or need 97 for invasive or non-invasive mechanical ventilation) above baseline. For this study, we analyzed 98 samples from thirty-one critically ill patients with severe COVID-19 disease (SARS-CoV-2 99 RNA+) (n=31), between 28 and 69 years of age. Patients with current malignant diseases, 100 ongoing immunomodulatory treatment before hospitalization, and known diabetes mellitus were 101 excluded. Seventeen healthy controls (Control) that were SARS-CoV-2 immunoglobulin G (IgG) 102 seronegative and symptom-free at sampling were recruited as controls, with ages ranging from 103 25 to 65 years old. To minimize inter-experimental variability and batch effects between patients 104 and controls, all samples (n=77) were acquired, processed, and analyzed fresh during the 105 period between April 2020 and January 2021. Another group of individuals at an age range of 106 24 to 60 were recruited after three months of recovery from COVID-19 infection (n=29)

107 (Recovered) at the peak of the COVID-19 pandemic in the United States (August 2020). 108 Supplementary Table 1 and Materials and Methods both provide more specific patient 109 characteristics. To study the innate cell response, we stained fresh whole blood with a 20-color 110 innate cell-focused flow cytometry panel. All clinical laboratory analyses, including serology 111 and polymerase chain reaction (PCR) for SARS-CoV-2, were performed using clinical routine 112 assavs in the clinical laboratories at The Ohio State University Wexner Medical Center. 113 Columbus, Ohio. We obtained approval by the Research Ethics Committee in The Ohio State 114 University under following IRB protocols (2020H0175, 2020H0228, 2014H0467, 2020H0339) 115 and all patients gave written informed consent. For detailed clinical information, see 116 Supplementary Table 1. 117

118 Flow cytometry staining and Data acquisition: Patients underwent a blood draw performed 119 by a trained phlebotomist. Peripheral blood from healthy donors and patients was collected into 120 sodium citrate tubes (BD, Franklin Lakes, NJ) and whole blood staining was performed. After 121 collection, 120µL of whole blood was separated into polystyrene FACS (fluorescence-activated 122 cell sorting) tubes and red blood cells were lysed using ACK buffer (Thermofisher, Waltham, 123 Massachusetts) for 5 minutes followed by a wash with R10 media (RPMI-1640 supplemented 124 with 10% FBS [fetal bovine serum], 2 mM L glutamine, 100 U/mL penicillin, and 100mg/mL 125 streptomycin). After washing with phosphate-buffered saline (PBS), cells were pre-stained for 126 viability exclusion using Zombie NIR Fixable Viability dye (BioLegend, San Diego, California) for 127 10 minutes, followed by a 20-minute incubation with a panel of directly conjugated monoclonal 128 antibodies and TruStain diluted in equal parts of FACS buffer (PBS containing 0.1% sodium 129 azide and 1% bovine serum albumin) and Brilliant Stain Buffer (BD Biosciences, San Jose, 130 California). After staining, cells were fixed with 2% paraformaldehyde and were filtered by using 131 filter caps for polystyrene FACS tubes before being acquired on a Cytek Aurora, a multispectral

flow cytometry system with, 405-, 488-, and 640-nm lasers. Monoclonal antibodies used in thepanel can be accessed in Supplementary Table 2.

134 Flow cytometry data analysis: FCS files were exported from spectralflo software and imported 135 into FlowJo v.10.6.2 for subsequent analysis with the use of the following plug-ins to visualize 136 the data: DownSample (3.2), and t-distributed stochastic neighbor embedding (tSNE). First, the 137 compensation matrix for the 20-color flow cytometry panel was generated to correct for 138 fluorescence spillover emissions and applied to files. Dataset as such was used for the 139 downstream analysis in both manual gating (Supplementary Fig.1) and automated analysis. For 140 the automated analysis, events were first down-sampled from the CD45<sup>+</sup> CD3<sup>-</sup> CD19<sup>-</sup> gate 141 across all samples using Down Sample. Clinical parameter categorical values for each sample 142 were added to downsampled populations as metadata to enable identification of these groups. 143 and these were then concatenated for analysis. tSNE was run using all parameters from the 144 panel except Zombie NIR (Live/Dead), BV711(CD19), FITC(CD45) and APC-Cy7 (CD3). 145 After generating the tSNE figures, manually gated immune cell subsets were overlaid to the 146 figures to represent subsets from each cohort. (e.g., 17 "healthy controls," 31"severe," and 29 147 "recovered" patients). Computational analysis of flow cytometry data for monocytes were 148 visualized by uniform manifold approximation and projection (UMAP) embedding. UMAP 149 dimensionality reduction was done on the dataset using all parameters from the panel except 150 Zombie NIR (Live/Dead), BV711(CD19) FITC(CD45) and APC-Cy7 (CD3). The data were 151 projected in 2-dimensions using UMAP embeddings and clusters of major monocyte subsets 152 were identified based on expression of lineage defining markers. We used R (version 4.2.1) with 153 packages gppubr, gpplot, psych, gridExtra, corrplot<sup>8,9</sup> to generate figures.

154

Measurements of inflammatory biomarkers, chemokines, and cytokines: The plasma
collected from blood samples was stored at -20°C and batched until processing without a prior
thaw. Using enzyme-linked immunosorbent assay (ELISA), the following inflammatory markers

158 were measured (Supplementary Table 3) including: Tissue inhibitor of metalloproteinases-1 159 (TIMP-1), Tissue inhibitor of metalloproteinases-2 (TIMP-2), Monocyte chemotactic protein 1 160 (MCP-1), Lipoprotein-Associated Phospholipase A2 (LpPLA2), oxidized low-density lipoprotein 161 (Ox-LDL). To detect plasma cytokine and chemokine levels, plasma samples were processed 162 using the multiplexed ELISA-based platform Quantibody® Human Inflammation Array 3 (RayBiotech QAH-INF-3) in accordance with the manufacturer's protocol. Raw optical data were 163 164 analyzed using the manufacturer's analysis tool to construct standard curves and determine 165 absolute cytokine concentration.

166

167 **In-vitro Ox-LDL uptake experiment:** An in-vitro experiment was conducted to investigate the 168 role of activated NK cells in the uptake of Ox-LDL by macrophages. 5ml of venous blood 169 samples were collected from severe COVID-19 patients (n=6) in sodium citrate tubes, and 170 Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll gradient centrifugation. 171 The isolation of NK cells was performed using the Miltenyi Biotec NK cell isolation kit (130-092-172 657). Subsequently, NK cells were activated in vitro through incubation with autologous plasma. 173 Concurrently, PBMCs were allowed to rest and were incubated in Teflon-coated wells for up to 174 six days. This incubation stimulated the development of monocyte-derived macrophages (MDMs) from peripheral blood monocytes<sup>10</sup>. After six days, these monocyte-derived 175 176 macrophages were exposed to a medium containing Ox-LDL, which had been commercially 177 manufactured and dye-tagged with Dil, to assess the absorption of Dil-Ox-LDL (10 ug/mL). This 178 assessment was carried out after a four-hour incubation period in the presence or absence of 179 plasma-activated NK cells. The cells were subsequently washed twice with PBS, and the 180 intensity of Dil staining was measured using flow cytometry. To identify macrophages, markers 181 such as CD45, CD3, CD19, and CD14 were utilized. For fluorescence microscopy analysis, the 182 cells were seeded into 12-well plates and incubated at 37°C for an additional 24 hours. Images

were acquired using an EVOS microscope, and the presence of Dil was detectable using an
 RFP filter (absorption peak: ~554 nm, emission peak: ~571 nm).

scRNA-seq data analysis: scRNA-seq data were obtained from a published dataset<sup>11</sup> The data 185 186 file (in 'rds' format) downloaded from the cellxgene Data Portal (https://cellxgene.Cziscience 187 .com /datasets) were read into R (version 4.2.1) session. Quality control was performed using 188 Seurat (v3.1.5) to identify and filter out low-guality cells based on mitochondrial content and 189 performing data preprocessing to prepare the data for downstream analysis. Cells with a 190 percentage of mitochondrial genes greater than 10% were considered low quality and were 191 filtered out. Prior to downstream analysis, the dataset was scaled and centered using 192 "NormalizeData" and "ScaleData" functions. As the focus was on NK cells and monocytes and 193 comparison between severe and control groups, specific subsets of scRNA-seq data set were 194 separated and merged based on their metadata. The reanalysis included the standard Seurat 195 workflow with "RunPCA" and the number of Principle component analysis (PCA) dimensions 196 used was 30, with a resolution parameter of 0.5. An elbow plot was generated to determine the 197 optimal number of principal components for downstream analysis. UMAP plots were generated 198 to visualize the cell clusters and identify potential subpopulations. After the cell clusters had 199 been obtained, the Differentially expressed genes (DEG) in each cluster was computed with 'FindAllMarkers' (Supplementary Table 4)<sup>12,13</sup>. Marker genes were determined based on their 200 201 average log-fold change (log<sub>2</sub>FC) and statistical significance (p-value and q-value). 202 Gene Ontology (GO) enrichment analysis was performed to gain insights into the biological 203 processes associated with a set of genes of interest. The analysis was carried out using the clusterProfiler package in R (version 4.2.1)<sup>13</sup>. The significance threshold for enriched GO terms 204 205 was set at a p-value cutoff of 0.05, and the Benjamini-Hochberg method was applied for multiple 206 testing correction using GO terms with a q-value (adjusted p-value) below 0.05 were considered 207 statistically significant. Cytoscape software (version 3.10.0) was used to visualize significant

208 GO terms and integrate the GO terms to create a GO pathway network. For the DEGs, Kyoto

Encyclopedia of Genes and Genomes (KEGG) pathway enrichment was performed for the top 200 DEGs. Enrichment analysis of the converted Entrez IDs was conducted to determine the significant KEGG pathways associated with the DEGs. The enrichKEGG function from the clusterProfiler package was utilized, specifying the gene IDs and the organism of interest (Homo sapiens, organism code 'hsa')<sup>14</sup>. This function identified overrepresented pathways based on a hypergeometric test. We employed the cnetplot function, to show the hub genes and pathways enriched.

216

217 Statistical Analysis: Graphs and heatmaps were prepared using GraphPad Prism, version 9. Data were statistically analyzed used their bundled software. One-way ANOVA<sup>15</sup> was used to 218 219 compare three or more groups followed by Dunn's multiple comparisons test for pairwise 220 comparisons. Comparisons between two groups were performed using the Wilcoxon rank-sum 221 test. To analyze the relationship between immune signatures and plasma biomarkers. Pearson 222 correlation coefficient was calculated and plotted on a correlogram using R 4.2.1. Scatter plots 223 showing linear relationships between data was created for significant correlations. Data 224 visualization was achieved using functions from the Seurat, ggplot2, and pheatmap packages. 225

226 **Results**:

227 Study design and cohort demographics: In this cross-sectional study, we assessed the 228 immune profile in fresh whole blood samples from patients across three groups: 1) healthy 229 donors: seventeen healthy age/sex-matched adults (n=17) who were SARS-CoV-2 230 immunoglobulin G (IgG) seronegative and asymptomatic at sampling as controls, 2) patients 231 with severe COVID-19: thirty-one patients (n=31) with sampling on day one of intensive care 232 unit admission for severe COVID-19 and respiratory failure, and 3) recovered patients: twenty-233 nine individuals with complete clinical recovery (n = 29) sampled three months after severe 234 COVID-19 infection. Supplementary Table 1 and Materials and Methods both provide more

235 specific patient characteristics. To minimize inter-experimental variability between patients and

controls, all samples (n=77) were acquired, processed, and analyzed fresh between April 2020

and December 2020. Samples were analyzed using a 20-color spectral flow cytometer

238 (Supplementary Table 1, gating strategy in Supplementary Fig.1).

239

240 Temporal dynamics of innate immune signatures and dysregulations in severe COVID-241 **19:** We applied conventional flow cytometry and tSNE dimensionality reduction plots gated on 242 CD45<sup>+</sup>CD3<sup>-</sup>CD19<sup>-</sup> cells, which allowed for the identification and visualization of 10 innate 243 immune cell populations (Fig.1A). The clustering algorithm allowed for an unbiased 244 representation of these clusters during each stage of the disease. Among the dominant innate 245 cell subsets that were focused on this study, we observed a significant increase in the 246 frequencies of eosinophils (p<0.05) and neutrophils (p<0.05) among severe covid-19 patients 247 (Fig.1B). While no differences were observed in the frequency of total monocytes between the 248 control and severe groups, an overall increase in their frequencies was observed following 249 recovery (p<0.05). Total NK cell frequencies were significantly decreased during severe 250 infection and returned to basal levels after recovery, similar to previously published data<sup>16</sup>. We 251 next analyzed the connectivity of cellular profiles and cytokine levels (detailed in Fig.2) in each 252 study group. Heatmaps depicting correlation between 48 plasma cytokines/chemokines and 10 253 major innate immune cell subsets for the control, severe and recovered groups constructed 254 based on Pearson correlation coefficient (Fig.1C). The correlation coefficients between those 255 cell subsets were used to construct the density plot for each group. The density plot for Pearson 256 correlation coefficients between three groups (control, severe, and recovered) comparing 257 immune cell and cytokine data, provides a visual representation of the distribution of correlation 258 coefficients for various pairs of variables between these groups (Fig.1D). Each line on the 259 density plot represents one of the groups, and the plot can help reveal central tendency, spread 260 and variability. A higher peak indicates a stronger central tendency toward certain correlation

261 values. Visually comparing the three density lines, you can assess differences or similarities in 262 the correlations between the groups. Comparing the three group's density lines, we observe a 263 greater overlap between severe and recovered group, compared to controls. Overall, the 264 correlograms and density plots imply that the recovered donor group has a more similar 265 distribution to severe patients than to the controls. PCA also revealed that three groups have 266 differential cellular and cytokine profiles (Fig.1E). The volcano plot (Fig.1F) visualizes a 267 sustained dysregulation of immune and biochemical parameters despite recovery from the 268 disease. Overall, our data suggest that severe COVID-19 patients' innate cell responses are 269 dysregulated, with some immune perturbations persisting even after assumed viral clearance 270 and recovery (up to 90 days post-infection).

271

272 Differential inflammatory and cardiovascular biomarker profiles following severe COVID-273 **19:** Next, we analyzed 48 cytokines, chemokines, and plasma biomarkers related to 274 cardiovascular risk, including those associated with the 'cytokine storm' and post-acute 275 sequelae of SARS-CoV-2 infection, in plasma samples (Fig.2A). Interestingly, seven of 33 276 increased cytokine responses in the severe patients were also increased in the recovered 277 population. Nine cytokines were decreased in severe patients and the recovered donors 278 compared to levels in the healthy donors (Fig.2A). For a broader comparative analysis of 279 proinflammatory protein profiles that exhibited differential expression among our study cohorts, 280 we executed PCA on all the proteins identified in the plasma (Fig.2B). The control, severe, and 281 recovered groups displayed distinct clustering, signifying significant dysregulation of 282 inflammatory proteins both during and after severe COVID-19 infection. Interestingly, our 283 findings reveal that metalloproteinase inhibitors, specifically TIMP-1 and TIMP-2, which are 284 recognized for their pivotal roles in atherosclerosis, plaque development, and platelet 285 aggregation<sup>17</sup>, were elevated in severe patients (Fig.2C and Fig.2D) and persisted even three 286 months after recovery from severe COVID-19. We also found increased levels of MCP-1

287 (Fig.2E), which is known to mediate migration and infiltration of monocytes to tissues, in severe-288 COVID-19 patient's plasma. We also found an increase in Interferon-gamma inducible Protein 289 10kDa (IP-10) (Supplementary Fig.2A), and decreased levels of CCL5/RANTES (Regulated on 290 activation, normal T cell expressed and secreted) (Supplementary Fig.2B) and eotaxin 291 (Supplementary Fig.2D) in severe patients compared to levels in the other groups. Levels of 292 cardiometabolic and inflammatory biomarkers, including soluble CD14 (sCD14), 293 lipopolysaccharide-binding protein (LBP), fatty acid binding protein 4 (FABP4), D-Dimer, C 294 reactive protein (CRP), and tissue factor (Supplementary Fig.2), were elevated during severe 295 disease, but levels in healthy and recovered participants were similar (Supplementary Fig.2). 296 Notably, CRP and D-dimer levels, indicative of COVID-19 severity, may correlate with 297 complications like acute respiratory distress syndrome (ARDS) and cardiovascular events. 298 Unexpectedly, levels of Ox-LDL and LpPLA2 were decreased in severe and recovered patients, 299 compared to levels in healthy controls (Fig.2F-G). This surprising finding highlights a persistent 300 disruption in mechanisms involving modified lipoprotein homeostasis during and after severe 301 COVID-19 infection.

302

303 Monocyte subset dynamics in COVID-19: Implications for immune dysregulation. Next, 304 we examined monocyte subsets in our study populations. We observed elevated levels of 305 CD14<sup>++</sup>CD16<sup>-</sup> "classical" monocytes in the recovered donors' whole blood compared to the 306 other two groups (Fig.3A and B). In contrast, intermediate monocytes (CD14<sup>++</sup>CD16<sup>+</sup>) were 307 increased in severe patients (Fig.3B), while the frequency of CD14<sup>-</sup>CD16<sup>+</sup> "non-classical" 308 monocytes was reduced in severe COVID-19 patients. Monocytes were visualized in a two-309 dimensional space using UMAP in Flowjo 10.9.0 (Fig.3C), which showed unique sub-clusters 310 depending on the disease condition. Control and recovered groups had similar clustering 311 patterns, distinct from the severe group, and some island clusters exhibited differences, 312 suggesting varying features between these cohorts. No statistically significant changes were

313 observed in CD27, CXCR3, and PD-1 receptor expression in classical and intermediate 314 monocytes. However, the trend for decreased expression in PD-1 and increased CXCR3 315 expression in non-classical monocytes in the severe COVID-19 group suggests a more 316 proinflammatory phenotype displayed by this subset (Fig.3D and Supplementary Fig.3C). We 317 noted significant increases in CXCR5-expressing intermediate monocytes among our study 318 populations compared to controls, with elevated frequencies persisting from severe disease into 319 the recovery phase (Fig.3D and E). Similar monocyte/macrophage subsets have previously been reported in atherosclerotic lesions<sup>18</sup>. In contrast, severe COVID-19 patients exhibited low 320 321 levels of intermediate and classical monocytes expressing tissue residency markers (e.g., 322 CD69) in their peripheral circulation, and this reduction was also seen in the recovered group 323 (p<0.05) (Fig.3D, and F). Our results indicate persistent dysregulation of circulating monocytes 324 post-COVID-19 recovery, involving alterations in frequencies, subsets, and functional markers.

325

326 Dysregulated NK cell phenotypes associated with COVID-19 infection. We and others have observed that COVID-19 infection alters total NK cell frequencies in peripheral blood<sup>16,19</sup>. Using 327 328 a previously described gating strategy, CD56 and CD16 receptor expression were used to identify five distinct NK cell subsets<sup>20</sup> (Fig. 4A and B). NK cell subsets clustered differently 329 330 among the three groups. Overall, patients with severe illness had considerably lower 331 frequencies of all five NK cell subsets (Fig.4D). Furthermore, these subsets showed noticeable 332 differences between groups in terms of expression of activation and tissue homing markers (Supplementary Fig.4). In all NK subsets, CD69, a marker of activation and tissue residency<sup>21</sup> 333 334 was increased in individuals with severe COVID-19. Levels of CD69 on NK cell subsets was 335 similar between healthy and recovered donors (Fig.4F). We also noted an increasing trend in 336 HLA-DR expression during severe infection, suggesting NK cell activation during severe disease (Fig. 4G). Additionally, NKG2A expression (indicating an inhibitory NK phenotype)<sup>22</sup> 337 338 was decreased among NK subsets in severe COVID-19 patients (Supplementary Fig.4B).

confirming NK cell activation during severe infection. We also noted significantly lower
expression of CD27 in three of the NK subsets except CD56<sup>dim</sup>CD16<sup>-</sup> and CD56<sup>-</sup>CD16<sup>dim</sup>
subsets in severe COVID-19 patients and recovered donors compared with controls (Fig.4E).
CD27<sup>+</sup> NK cells are particularly important in mediating NK cell /T cell interaction via the CD27CD70 pathway<sup>23</sup>.

344

345 Implications of activated NK cells and monocytes on Oxidized LDL levels and potential 346 atherogenesis in severe COVID-19: In order to determine whether the changes we observed 347 in innate cells were related to cardiometabolic biomarker levels, we performed Pearson 348 correlational analysis to assess associations between plasma biomarker data acquired through ELISA and flow cytometry immune cell frequencies. As shown in Fig.2F and G, while most 349 350 biomarkers returned to basal levels after recovery, Ox-LDL and LpPLA2 (which co-traffics Ox-LDL into tissue) levels remained decreased significantly even after recovery. Ox-LDL is 351 352 recognized as a key player in the development of atherosclerosis (atherogenesis)<sup>24</sup>. We 353 identified multiple correlations between immune cell data and plasma Ox-LDL (Fig.5A and B). 354 We discovered a strong negative correlation between CD69<sup>+</sup> NK cells and Ox-LDL levels 355 (Fig.5C-D and Supplementary Fig.5A-D) as well as a negative correlation between Ox-LDL and 356 activated (CD69<sup>+</sup>) total monocytes (Fig.5F), activated (CD69<sup>+</sup>) classical monocytes (Fig.5G) and 357 intermediate monocytes (Fig.5H) among our severe COVID-19 patients. Monocytes migrate into the arterial wall and differentiate into macrophages, where these cells can internalize Ox-LDL 358 and transform into foam cells<sup>25</sup>. Therefore, our findings suggest a novel mechanism underlying 359 360 the reduction of Ox-LDL levels in severe COVID-19 patients, potentially driven by activated NK 361 cells contributing to increased consumption of Ox-LDL from the circulation by MDMs, leading to 362 increased foam cell formation and subsequent atherogenesis in COVID-19 patients.

363

### 364 Transcriptional profiling and functional differentiation of monocytes and NK cells in

365 severe COVID-19: We validated the phenotypic changes observed in flow cytometry and 366 plasma biomarker assays using a publicly available single-cell RNA sequencing (scRNA-seq) 367 dataset from Schulte-Schrepping et al.<sup>11</sup> For both NK cells and monocytes, we identified 2307 368 and 1815 DEGs (adjusted p-value < 0.05 & positive log<sub>2</sub>FC) (Supplementary Fig.6A), selecting 369 the top 200 DEGs for GO enrichment analysis (Supplementary Table 4 and 5). UMAP figures in 370 Supplementary Fig.6B showcased immune cell annotations and clustering based on disease 371 condition (control vs. severe COVID-19), with DEG analysis separately conducted for NK cells 372 and monocytes. Heatmaps in Supplementary Fig.6C (monocytes) and Fig.6D (NK cells) 373 provided an overview of transcriptional profile differences. Our analysis, incorporating the top 374 200 DEGs, revealed that transcriptional profiles phenotypically and functionally distinguished 375 severe COVID-19 patients from uninfected counterparts. Volcano plots (Supplementary Fig.6D 376 and E) displayed upregulated (red) and downregulated (green) genes. Our flowcytometry 377 analysis revealed that severe patients and recovered donors both exhibited an increased 378 presence of intermediate monocytes (as shown in Fig.2B). This difference was found to be 379 statistically significant (p<0.05). Incidentally, our transcriptome analysis revealed an 380 upregulation of CD36, a gene known to be more expressed in intermediate monocytes. CD36 381 encodes a receptor for Ox-LDL, and it plays a role in binding and internalizing Ox-LDL. 382 Additionally, our analysis predicted multiple epigenetic modifications occurring as a result of 383 severe infection. This prediction was corroborated by a high number of DEGs associated with 384 histone modification and DNA methylation. Examples of these genes include H1-4, H1-3, H1-10, 385 H1-2, and SETD2 (Supplementary Table 4). In monocytes, we observed significant 386 upregulation in expression of CXCL2, IL1b and NLRP3 other notable genes suggestive of a 387 proinflammatory phenotype in monocytes. (Fig.6A & Supplementary Table 4). Similarly, in NK 388 cells, we detected upregulation of genes indicative of migration, inflammation, and activation, 389 including ICAM3, TNFAIP3, CD69, and IL12RB1 (Fig.6B & Supplementary Table 4). Some

390 genes like *ICAM3, TNFSF12, TNFSF1214, NLRP3* and *BRD2* were upregulated in both cell
391 types (Supplementary Table 4).

392

393 Pathway analysis reveals intriguing interplay between viral response and lipid storage 394 regulation in macrophages, highlighting persistent changes in innate cells: Furthermore, 395 we conducted GO enrichment analysis to explore the functional enrichment of the DEGs, and 396 the KEGG database was used to group these differentially expressed genes into gene 397 pathways. We utilized the GO database and considered GO terms with a p-value < 0.05398 significantly enriched (Fig6C-D & Supplementary Table 5). Our analysis revealed significant 399 enrichment in GO terms associated with lasting cellular epigenetic changes. This pattern was 400 consistent in both NK cells and monocytes during severe infection. Both cell types showed 401 enriched pathways related to dysregulated unfolded protein response, particularly regulation of 402 endoplasmic reticulum (ER) stress. In monocytes, we found significant enrichment in GO terms 403 like "leukocyte chemotaxis", "myeloid leukocyte migration", and "phagocytosis engulfment", 404 suggesting potential activation and differentiation of migratory, phagocytic macrophages. In NK 405 cells, GO pathway analysis highlighted the importance of "defense response to virus" and "viral-406 induced Pattern recognition receptor (PRR) pathway signaling" in combating SARS-CoV-2 407 infection.

408 Interestingly, we observed an overlap between DEGs and enriched GO terms in NK cells and 409 monocytes. Genes like STAT, TNFAIP3, and NFKBIA were differentially expressed and 410 enriched in multiple GO terms. We used Cytoscape v3.10.0 to create network visualizations of 411 enriched GO pathways for monocytes (Fig.6E) and NK cells (Fig.6F). The monocyte network 412 has 57 nodes, while the NK cell network has 39 nodes, each representing a specific GO 413 pathway. The edges between nodes indicate potential relationships between pathways based 414 on shared genes. Lighter node colors indicate greater statistical significance for pathway 415 enrichment. Connections between pathways in the network imply shared genes, suggesting

416 possible crosstalk or cooperation in biological processes. Node color signifies pathway 417 enrichment significance, and lighter shades indicate stronger significance. Edges represent 418 shared genes, hinting at potential functional links, like crosstalk or cooperation between 419 pathways due to shared genes in biological processes. In monocytes, a significant network 420 emerges with interconnected pathways such as macrophage activation, phagocytosis, ER 421 stress, acute inflammatory response, and lipid storage regulation. This network has the potential 422 to fuel atherogenesis through immune system activation. A prominent connection arises in NK 423 cells between defense response to viruses, PRR signaling, and stem cell differentiation 424 regulation. This suggests that NK cells, when encountering viruses, adopt an activated 425 migratory phenotype, potentially becoming dominant in circulation. Furthermore, the KEGG 426 pathway analysis (Supplementary.Fig.6G-H) adds another layer of evidence to the notion of 427 enduring alterations in innate cells and their potential impact on the post-acute consequences of 428 SARS-CoV-2 infection. The amalgamation of differential gene expression and GO enrichment 429 analysis offers a holistic understanding of the molecular terrain associated with severe COVID-430 19 and the enduring modifications in innate cells. This insight can potentially reveal valuable 431 biomarkers and therapeutic targets for further exploration.

432

433 Enhanced Ox-LDL uptake by monocyte-derived macrophages in the presence of 434 autologous NK cells treated with plasma from severe COVID-19 patients: Based on our 435 observations of innate immune responses and plasma biomarkers in vivo and analysis of 436 published single-cell data, we have identified a significant correlation between multiple activated 437 NK cell subsets and plasma Ox-LDL. Our findings strongly imply that these activated NK cells 438 play a pivotal role in enhancing the uptake of circulating Ox-LDL. To further investigate the 439 contribution of activated NK cells to atherogenesis and substantiate our hypothesis, we 440 conducted an in vitro experiment to explore the impact of activated NK cells on Ox-LDL uptake 441 by macrophages (Fig.7A).

442 We employed a method as outlined in one of our earlier publications. Frozen PBMCs from 443 severe COVID-19 patients (n = 6) were used to isolate NK cells. These NK cells were 444 subsequently incubated with autologous plasma. Concurrently, autologous MDMs were 445 generated from the same patient's PBMCs by allowing them to rest in Teflon-coated wells for up 446 to six days. Following a six-day incubation period, we incubated these MDMs for four hours with 447 commercially manufactured Dil-labeled Ox-LDL, both in the presence or absence of activated 448 autologous NK cells. Interestingly, we observed significantly higher Dil-Ox-LDL uptake in the 449 presence of activated NK cells (Wilcoxon signed rank-test; p<0.05 for all) (Fig.7B and C). The 450 levels of Dil-Ox-LDL were quantified using flow cytometry, and this was further confirmed 451 through EVOS microscope images (Fig.6D). Microscopic images were acquired to detect cells with internalized Dil-Ox-LDL using an RFP/TRITC filter set (absorption peak: ~554 nm, 452 453 emission peak: ~571 nm). In summary, our findings collectively suggest that activated NK cells, 454 in conjunction with other plasma factors, may be linked to increased Ox-LDL uptake and 455 increased cardiovascular risk in individuals with severe COVID-19.

456

### 457 **Discussion:**

458 The COVID-19 pandemic has shed light on a range of health concerns beyond acute respiratory 459 symptoms of the disease, including atherosclerotic cardiovascular disease. Given that evidence 460 from genome-wide association studies, imaging techniques and clinical intervention studies confirm innate immune involvement in accelerating atherosclerosis<sup>26</sup>, it is likely that the immune 461 462 perturbations following SARS-CoV-2 infection may be a key driver in COVID-19 associated 463 CVDs. Our study provides mechanistic evidence to support the importance of unique macrophage-NK crosstalk during severe COVID-19 infection in promoting long-term 464 465 atherogenesis. We show that in the proinflammatory environment of severe COVID-19, subsets 466 of NK cells with altered phenotypes help macrophages take up modified lipids (Ox-LDL) and enhance foam cell generation. Our study also highlights a persistence of the pro-atherogenic 467

potential following recovery from severe COVID-19, as evidenced by these innate immune
alterations and disturbances in cardiometabolic biomarkers persisting up to three months after
recovery.

471 Monocytes and macrophages play a crucial role in the development of atherosclerosis, both as mediators of chronic inflammation and plaque generation through lipid uptake<sup>27</sup>. Monocytes 472 473 migrate from the bloodstream to the vessel wall, where they transform into tissue macrophages. 474 These tissue macrophages subsequently convert into foam cells by taking up modified cholesterol, in particular Ox-LDL, initiating atherogenesis<sup>28</sup>. Our observations of significant 475 476 increases in circulating intermediate monocytes in our severe COVID-19 patients (and 477 remaining elevated post-recovery) suggests that atherogenesis may occur more readily during 478 and after severe COVID-19 infection, as proinflammatory monocyte subsets such as these have 479 a greater potential for trans-endothelial migration and vessel wall adhesion<sup>5</sup>. Increased CXCR5 480 expression in this monocyte subset among both severe COVID-19 patients and those who 481 recovered further enhances their chemotactic potential towards inflamed vascular intimal tissue rich in its ligand CXCL13<sup>29</sup>. In addition, we noted elevated levels of other chemokine ligands like 482 483 MCP-1<sup>30</sup> in the plasma of severe COVID-19 patients. This may be a valid explanation to our 484 observations of decreased CD69-expressing intermediate (tissue-resident) monocytes in the 485 circulation of severe COVID-19 patients. Simultaneous reductions in Ox-LDL and LpPLA2 486 during severe infection, persisting even after recovery may indicate ongoing consumption of 487 these atherogenic mediators. This may suggest that these intermediate monocytes leaving the 488 circulation to transform into intimal macrophages may play a role in Ox-LDL consumption. Contradicting evidence suggest that in COVID-19 patients, during early recovery, higher levels 489 of Ox-LDL are likely to be observed<sup>31</sup>. However, these studies did not account for other risk 490 491 factors of atherosclerosis and those which dysregulate lipid metabolism, including diabetes 492 mellitus and hypertension. Considering the fact that we excluded majority of these factors 493 suggest their exclusion may influence the outcome of our data which shows the onset of

atherogenesis and role of Ox-LDL uptake in its early stages. Our analyses of transcriptome 494 495 data from PBMCs of severe COVID-19 patients from external databases support our high-496 dimensional flowcytometry analyses, revealing enrichment in transcriptional pathways 497 supporting chemotaxis, migration, phagocytosis, plasma membrane invagination, and 498 engulfment, and upregulation of DEGs encoding macrophage scavenger receptors like CD36, 499 SR-A and those involving lipid storage. 500 Monocytes/macrophages are the most investigated immune cells in atherosclerosis. However, 501 there is now increasing preclinical and clinical evidence that NK cells play a significant role in its pathogenesis. Traditionally considered immune defenders against viruses<sup>32,33</sup> and cancer<sup>34</sup>, this 502 503 heterogenous group of immune cells are now increasingly recognized for their diverse roles, 504 including those related to disease pathogenesis. In the case of human atherosclerosis, most of 505 the current knowledge on NK cell involvement comes from observational studies on 506 atherosclerotic lesions using immunohistochemistry. Bonaccorsi et al. characterized NK cells in 507 atherosclerotic plaques of asymptomatic patients and found that these were enriched in CD56<sup>bright</sup>perforin<sup>low</sup> NK cells, which also expressed tissue-resident markers such as CD69<sup>35</sup>. 508 509 While we and others have shown overall reductions in circulating NK cells during acute COVID-19<sup>16</sup>, we have also seen significantly increased expression of CD69 in these NK cells and their 510 511 strong negative association with plasma Ox-LDL, suggesting that these NK cells may be linked 512 to processes involving uptake of Ox-LDL from the circulation into tissue. Cytokines like TNFa, 513 among the other proinflammatory cytokines that likely flood the circulation during the cytokine 514 storm of acute severe COVID-19, are known to be key modulators of NK cell cytotoxicity, 515 cytokine production, and adhesion molecule upregulation, and influences receptor expression, 516 including activating receptors like NKG2D and CD69. As evidenced by our NK cell

517 transcriptional analysis showing enrichment of the chemokine signaling pathway, these

518 activated NK cells may be increasingly recruited to inflamed tissue to eliminate infected cells<sup>36</sup>.

519 However, excessive NK cell activation can also promote tissue damage and inflammation.

520 Within this microenvironment, macrophages are reported to express NKG2D ligands (such as

521 Major Histocompatibility Complex class I chain-related proteins A, MICA) suggesting the

522 potential for direct macrophage-NK cell interactions. These interactions are known to promote

523 macrophages to differentiate into proinflammatory M1 phenotype<sup>37</sup>.

Netea et al. demonstrated that, in addition to microbial stimuli, endogenous metabolites, such as Ox-LDL, that are abundant in the plaque microenvironment, train pro-atherogenic monocytes and macrophages, possibly via epigenetic modifications which may be the key driver leading to ongoing atherogenesis despite recovery from acute SARS-CoV-2 infection<sup>38</sup>. This would substantially increase future CVD risk in previously infected individuals. Analysis of single cell transcriptome data of monocytes and NK cells found enriched pathways related to histone modifications, crucial for epigenetic changes, further confirming the possibility of trained

531 immunity following severe COVID-19 infection.

532 Within vascular intimal tissue, hydrolysis of Ox-LDL into oxidized fatty acids contribute to 533 endothelial dysfunction, inflammation, and foam cell formation which may alter vascular architecture<sup>39</sup>. Progressive atherogenesis and vascular remodeling, reflected by persistent 534 535 elevations in plasma TIMP-1 and TIMP-2 despite recovery<sup>40</sup> is likely to contribute to the 536 increased thromboembolic events documented following acute severe COVID-19 which has 537 drawn significant scientific interest<sup>41</sup>. Indeed, Severe COVID-19 patients in our study showed a 538 likely procoagulant state, evident from significantly elevated D-dimer levels, a marker of thromboembolic disease severity<sup>42</sup>. While the procoagulant state in COVID-19 is complex<sup>43</sup>, our 539 540 study suggests that unique dysregulations in monocyte/macrophage and NK cell activity may 541 contribute to thrombosis, by damaging the endothelium, promoting atherogenesis, and 542 disrupting wall architecture. This interpretation aligns with the classical Virchow's triad, which 543 describes factors contributing to thrombosis. NK cell infiltration in particular may additionally damage the endothelium and disrupt wall architecture via perforin and granzyme B<sup>44</sup> and 544

elevate tissue factor levels (as seen in our severe COVID-19 patients), initiating the coagulation
 cascade by combining with activated factor VII<sup>45</sup>.

547 Our study is limited to the analysis of a small, cross-sectional cohort of individuals with severe 548 COVID-19 infection. Furthermore, all samples were collected during the early phases of the 549 COVID-19 pandemic, and thus our findings are pertinent only to the SARS-CoV-2 strains that 550 circulated during that time in a pre-vaccination timeframe. Despite these limitations, our study 551 provides a novel perspective on the pathophysiological events driven by monocytes and NK 552 cells during severe COVID-19. These events ultimately contribute to atherogenesis and 553 coagulopathy, leading to enduring cardiovascular and thromboembolic disease risks. The 554 insights gained from this research pave the way for future therapeutic strategies aimed at 555 mitigating COVID-related cardiovascular and thromboembolic events by targeting these 556 mechanistic pathways.

557

## 558 Acknowledgments:

559 The authors gratefully acknowledge the support of all study individuals and their families. This

560 work was partially supported by National Center for Advancing Translational Sciences

561 (KL2TR002734 and UL1TR002733 to [J.S.B.]). We also, like to thank Sarah Karow and

562 Gabrielle Swoope for their efforts in sample collection and clinical coordination.

563

#### 564 **Author Contribution**:

565 M.G, Y.W and M.A performed experiments, data analysis and, wrote the manuscript. E.B, J.G

and A.K, performed lipid biomarker experiments. A.V. and A.K, performed cytokine experiments

and edited the manuscript. J.H, S.S, S.P, S.L and J.B coordinated clinical sample collection and

568 edited the manuscript. D.K and K.W. supervised data analysis, S.W and M.G performed

- transcriptome data analysis, N.F supervised lipid biomarker experiments and wrote the
- 570 manuscript, T.D, and N.L designed the study and wrote the manuscript.

## 571

572

- 573 Data Availability:
- 574 The data that support the findings of this study are available from the corresponding author
- 575 upon reasonable request.
- 576
- 577
- 578 References:
- 579 1 Kunutsor, S. K. & Laukkanen, J. A. Cardiovascular complications in COVID-19: A 580 systematic review and meta-analysis. *J Infect* **81**, e139-e141, 581 doi:10.1016/j.jinf.2020.05.068 (2020).
- Vilaplana-Carnerero, C. *et al.* Atherosclerosis, Cardiovascular Disease, and COVID-19: A
   Narrative Review. *Biomedicines* 11, doi:10.3390/biomedicines11041206 (2023).
- 5843Makarova, Y. A. et al. Atherosclerosis, Cardiovascular Disorders and COVID-19:585Comorbid Pathogenesis. Diagnostics (Basel) 13, doi:10.3390/diagnostics13030478586(2023).
- 587 4 Chaves, S. S. *et al.* Global, regional and national estimates of influenza-attributable 588 ischemic heart disease mortality. *EClinicalMedicine* **55**, 101740, 589 doi:10.1016/j.eclinm.2022.101740 (2023).
- 590 5 Kapellos, T. S. *et al.* Human Monocyte Subsets and Phenotypes in Major Chronic 591 Inflammatory Diseases. *Front Immunol* **10**, 2035, doi:10.3389/fimmu.2019.02035 (2019).
- 592 6 Eberhardt, N. *et al.* SARS-CoV-2 infection triggers pro-atherogenic inflammatory 593 responses in human coronary vessels. *bioRxiv*, doi:10.1101/2023.08.14.553245 (2023).
- 5947Michel, T., Hentges, F. & Zimmer, J. Consequences of the crosstalk between595monocytes/macrophages and natural killer cells. Front Immunol 3, 403,596doi:10.3389/fimmu.2012.00403 (2012).
- 5978Zou, C. et al. CD48 is a key molecule of immunomodulation affecting prognosis in glioma.598Onco Targets Ther 12, 4181-4193, doi:10.2147/OTT.S198762 (2019).
- 599 9 Zhou, X. *et al.* Novel Necroptosis-Related Gene Signature for Predicting Early Diagnosis
  600 and Prognosis and Immunotherapy of Gastric Cancer. *Cancers (Basel)* 14,
  601 doi:10.3390/cancers14163891 (2022).
- 60210Bowman, E. R. et al. Macrophage maturation from blood monocytes is altered in people603with HIV, and is linked to serum lipid profiles and activation indices: A model for studying604atherogenic mechanisms. PLoS Pathog 16, e1008869, doi:10.1371/journal.ppat.1008869605(2020).
- 60611Schulte-Schrepping, J. et al. Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell607Compartment. Cell 182, 1419-1440 e1423, doi:10.1016/j.cell.2020.08.001 (2020).
- 60812Zhao, G. et al. Single-cell RNA sequencing reveals the cellular heterogeneity of609aneurysmal infrarenal abdominal aorta. Cardiovasc Res 117, 1402-1416,610doi:10.1093/cvr/cvaa214 (2021).
- 61113Wu, T. et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data.612Innovation (Camb) 2, 100141, doi:10.1016/j.xinn.2021.100141 (2021).

- 4 Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing
  biological themes among gene clusters. *OMICS* 16, 284-287, doi:10.1089/omi.2011.0118
  (2012).
- Dixon, K. J. *et al.* MyD88 is an essential regulator of NK cell-mediated clearance of MCMV
   infection. *Mol Immunol* **137**, 94-104, doi:10.1016/j.molimm.2021.07.001 (2021).
- 618 16 Maucourant, C. *et al.* Natural killer cell immunotypes related to COVID-19 disease 619 severity. *Sci Immunol* **5**, doi:10.1126/sciimmunol.abd6832 (2020).
- Papazafiropoulou, A. & Tentolouris, N. Matrix metalloproteinases and cardiovascular diseases. *Hippokratia* 13, 76-82 (2009).
- Halvorsen, B. *et al.* Activated platelets promote increased monocyte expression of CXCR5
  through prostaglandin E2-related mechanisms and enhance the anti-inflammatory effects
  of CXCL13. *Atherosclerosis* 234, 352-359, doi:10.1016/j.atherosclerosis.2014.03.021
  (2014).
- Ahmed-Hassan, H. *et al.* Innate Immune Responses to Highly Pathogenic Coronaviruses
  and Other Significant Respiratory Viral Infections. *Front Immunol* **11**, 1979,
  doi:10.3389/fimmu.2020.01979 (2020).
- 62920Hartana, C. A. *et al.* Immune correlates of HIV-1 reservoir cell decline in early-treated630infants. Cell Rep 40, 111126, doi:10.1016/j.celrep.2022.111126 (2022).
- Duault, C. *et al.* Activated natural killer cells predict poor clinical prognosis in high-risk Band T-cell acute lymphoblastic leukemia. *Blood* 138, 1465-1480,
  doi:10.1182/blood.2020009871 (2021).
- Kamiya, T., Seow, S. V., Wong, D., Robinson, M. & Campana, D. Blocking expression of
  inhibitory receptor NKG2A overcomes tumor resistance to NK cells. *J Clin Invest* **129**,
  2094-2106, doi:10.1172/JCI123955 (2019).
- Titanji, K. *et al.* Altered distribution of natural killer cell subsets identified by CD56, CD27
  and CD70 in primary and chronic human immunodeficiency virus-1 infection. *Immunology* **123**, 164-170, doi:10.1111/j.1365-2567.2007.02657.x (2008).
- Hong, C. G. *et al.* Oxidized low-density lipoprotein associates with cardiovascular disease
  by a vicious cycle of atherosclerosis and inflammation: A systematic review and metaanalysis. *Front Cardiovasc Med* 9, 1023651, doi:10.3389/fcvm.2022.1023651 (2022).
- Khatana, C. *et al.* Mechanistic Insights into the Oxidized Low-Density Lipoprotein-Induced
  Atherosclerosis. *Oxid Med Cell Longev* 2020, 5245308, doi:10.1155/2020/5245308
  (2020).
- 646 26 Wolf, D. & Ley, K. Immunity and Inflammation in Atherosclerosis. *Circ Res* 124, 315-327, doi:10.1161/CIRCRESAHA.118.313591 (2019).
- Flynn, M. C., Pernes, G., Lee, M. K. S., Nagareddy, P. R. & Murphy, A. J. Monocytes,
  Macrophages, and Metabolic Disease in Atherosclerosis. *Front Pharmacol* 10, 666,
  doi:10.3389/fphar.2019.00666 (2019).
- 65128Marchio, P. *et al.* Targeting Early Atherosclerosis: A Focus on Oxidative Stress and652Inflammation. Oxid Med Cell Longev 2019, 8563845, doi:10.1155/2019/8563845 (2019).
- Smedbakken, L. M. *et al.* Increased levels of the homeostatic chemokine CXCL13 in
  human atherosclerosis Potential role in plaque stabilization. *Atherosclerosis* 224, 266273, doi:10.1016/j.atherosclerosis.2012.06.071 (2012).
- Lin, J., Kakkar, V. & Lu, X. Impact of MCP-1 in atherosclerosis. *Curr Pharm Des* 20, 45804588, doi:10.2174/1381612820666140522115801 (2014).
- Mouchati, C. *et al.* Increase in gut permeability and oxidized ldl is associated with postacute sequelae of SARS-CoV-2. *Front Immunol* 14, 1182544,
  doi:10.3389/fimmu.2023.1182544 (2023).
- 661 32 Vaccari, M. *et al.* Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. *Nat Med* **22**, 762-770, doi:10.1038/nm.4105 (2016).

- Liyanage, N. P. *et al.* Antiretroviral therapy partly reverses the systemic and mucosal distribution of NK cell subsets that is altered by SIVmac(2)(5)(1) infection of macaques. *Virology* 450-451, 359-368, doi:10.1016/j.virol.2013.12.003 (2014).
- Palano, M. T. *et al.* When a Friend Becomes Your Enemy: Natural Killer Cells in
  Atherosclerosis and Atherosclerosis-Associated Risk Factors. *Front Immunol* **12**, 798155,
  doi:10.3389/fimmu.2021.798155 (2021).
- 66935Bonaccorsi, I. et al. Symptomatic Carotid Atherosclerotic Plaques Are Associated With670Increased Infiltration of Natural Killer (NK) Cells and Higher Serum Levels of NK Activating671Receptor Ligands. Front Immunol 10, 1503, doi:10.3389/fimmu.2019.01503 (2019).
- Kumar, A. *et al.* SARS-CoV-2 cell entry receptor ACE2 mediated endothelial dysfunction
  leads to vascular thrombosis in COVID-19 patients. *Med Hypotheses* 145, 110320,
  doi:10.1016/j.mehy.2020.110320 (2020).
- 675 37 Weber, C. & Noels, H. Atherosclerosis: current pathogenesis and therapeutic options. *Nat* 676 *Med* **17**, 1410-1422, doi:10.1038/nm.2538 (2011).
- 677
   38
   Netea, M. G. *et al.* Defining trained immunity and its role in health and disease. *Nat Rev* 

   678
   *Immunol* **20**, 375-388, doi:10.1038/s41577-020-0285-6 (2020).
- 679 39 Chen, J. *et al.* Lp-PLA(2) (Lipoprotein-Associated Phospholipase A(2)) Deficiency Lowers
  680 Cholesterol Levels and Protects Against Atherosclerosis in Rabbits. *Arterioscler Thromb*681 *Vasc Biol* 43, e11-e28, doi:10.1161/ATVBAHA.122.317898 (2023).
- 40 Zureik, M., Beaudeux, J. L., Courbon, D., Benetos, A. & Ducimetiere, P. Serum tissue
  inhibitors of metalloproteinases 1 (TIMP-1) and carotid atherosclerosis and aortic arterial
  stiffness. *J Hypertens* 23, 2263-2268 (2005).
- Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA* 323, 1239-1242, doi:10.1001/jama.2020.2648 (2020).
- 689 42 Guan, W. J. *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl* 690 *J Med* 382, 1708-1720, doi:10.1056/NEJMoa2002032 (2020).
- Madoiwa, S. Recent advances in disseminated intravascular coagulation: endothelial cells
  and fibrinolysis in sepsis-induced DIC. *J Intensive Care* 3, 8, doi:10.1186/s40560-0150075-6 (2015).
- 694 44 Selathurai, A. *et al.* Natural killer (NK) cells augment atherosclerosis by cytotoxic-695 dependent mechanisms. *Cardiovasc Res* **102**, 128-137, doi:10.1093/cvr/cvu016 (2014).
- 696 45 Olson, N. C. *et al.* Soluble CD14, Ischemic Stroke, and Coronary Heart Disease Risk in a
  697 Prospective Study: The REGARDS Cohort. *J Am Heart Assoc* 9, e014241,
  698 doi:10.1161/JAHA.119.014241 (2020).

699